Supportive in acute allergic conditions, e.g. in anaphylactic shock in combination with adrenaline. Paroxysmal supraventricular arrhythmias including tachyarrhythmia in atrial fibrillation, unresponsive to standard anti-arrhythmic therapy.
Composition:
1 ml of solution contains 50 mg of antazoline mesylate.
Action:
The first generation antihistamine, which competitively blocks the histamine H receptor1. It also exerts cholinolytic and central inhibitory effects. It inhibits allergy symptoms, especially those associated with the release of histamine. Thanks to its anti-arrhythmic properties, it stabilizes cell membranes. It improves atrioventricular conduction, accelerating the frequency of ventricular rhythm in patients with atrial tachycardia and atrio-ventricular conduction block, and in patients with flutter or atrial fibrillation. After intravenous administration, it rapidly exerts an anti-arrhythmic effect, while the antiallergic effect occurs with a certain delay. Antazoline penetrates the blood-brain barrier and the placental barrier. It is metabolized in the liver and excreted mainly in the urine.
Contraindications:
Hypersensitivity to the components of the preparation. Glaucoma. Children under 12 years.
Precautions:
Antazoline should be avoided in patients with a history of epilepsy due to reports of convulsions. Use with caution in patients with hypertension, permanent arrhythmia, diabetes, hyperthyroidism or prostate hyperplasia. Avoid simultaneous use with MAO inhibitors, cholinolytics (phenothiazine derivative neuroleptics, hydroxyzine, tricyclic antidepressants), other antihypertensive drugs, as well as alcohol.
Pregnancy and lactation:
During pregnancy, use only if the anticipated benefits to the mother outweigh the potential risk to the fetus. Do not use during breast-feeding.
Adults: in allergic reactions intramuscularly: 200-300 mg per day; in the paroxysmal atrial fibrillation (within 3-10 min, under strict blood pressure and ECG monitoring): 100-300 mg (higher doses should be used in ICU conditions); drug administration should be discontinued after sinus rhythm returns. Children over 12 years of age with allergic reactions (temporarily) intramuscularly: 50-100 mg.
(C)
